Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1101 plus CHOP versus rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma
2018-002342-36Phase 3Completed
- Sponsor
- Eden Biologics, Inc.
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab biosimilar JHL1101, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Eden Biologics, Inc. Primary endpoint: Overall response rate after 6 cycles of treatment. Started Aug 2018; status: completed.
02
Drugs
rituximab biosimilar JHL1101rituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2018-002342-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002342-36.